Scarica l'app Stockscreener
7.68
2.81%
0.21
Precedente Chiudi:
$7.47
Aprire:
$7.69
Volume 24 ore:
1.05M
Relative Volume:
1.30
Capitalizzazione di mercato:
$545.49M
Reddito:
-
Utile/perdita netta:
$-119.87M
Rapporto P/E:
-4.2431
EPS:
-1.81
Flusso di cassa netto:
$-109.90M
1 W Prestazione:
-8.13%
1M Prestazione:
-23.20%
6M Prestazione:
-21.71%
1 anno Prestazione:
-25.58%
Intervallo 1D:
$7.44
$8.09
Intervallo di 1 settimana:
$7.34
$8.795
Portata 52W:
$6.33
$16.65
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Confronta ORIC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
7.68 | 545.49M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Wedbush Expects Reduced Earnings for ORIC Pharmaceuticals - MarketBeat
Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Earnings Beat - MarketBeat
ORIC Pharmaceuticals Inc (ORIC) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.6%Should You Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Oric Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 6.4%Should You Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at Guggenheim - MarketBeat
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
Oric recent weakness a buying opportunity, says JPMorgan - MSN
ORIC’s price-to-book ratio: An indicator of the company’s performance - US Post News
Jones Trading maintains Buy on ORIC, $17 target on positive data - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – What’s Next? - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at Guggenheim - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7%Time to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Given New $21.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating - TipRanks
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Optimistic Buy Rating for Oric Pharmaceuticals Driven by Promising Data and Favorable Risk/Reward Profile - TipRanks
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Consensus Price Target from Analysts - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for ORIC Pharmaceuticals (NASDAQ:ORIC) Stock - Armenian Reporter
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6%Here's Why - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharma's Latest Talent Investment: Strategic Equity Awards Unveiled - StockTitan
There is no doubt that ORIC Pharmaceuticals Inc (ORIC) ticks all the boxes. - SETE News
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - Knox Daily
Daily Market Movement: ORIC Pharmaceuticals Inc (ORIC) Sees a -2.59 Decrease, Closing at 10.15 - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC)’s stock chart: A technical perspective - US Post News
Citi maintains ORIC stock Buy rating, $13 target ahead of PFE data - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6% – Still a Buy? - Armenian Reporter
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data - Seeking Alpha
SG Americas Securities LLC Sells 3,256 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
JPMorgan Chase & Co. Increases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC Pharmaceuticals to Present at Three Major Healthcare Investor Conferences - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 5.6%Should You Buy? - MarketBeat
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oric Pharmaceuticals Inc Azioni (ORIC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):